© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 9, 662-669,
May 1, 2002
© 2002 Oxford University Press
ARTICLE |
Mastectomy and Oophorectomy by Menstrual Cycle Phase in Women With Operable Breast Cancer
Affiliations of authors: R. R. Love, Department of Medicine, Section of Medical Oncology, University of Wisconsin School of Medicine, Madison; N. B. Duc, N. V. Dinh, Hospital K, National Cancer Institute, Hanoi, Vietnam; T.-Z. Shen, People's Hospital of Haimen City, Haimen, Jiangsu, China; T. C. Havighurst, Department of Biostatistics and Medical Informatics, University of Wisconsin; D. C. Allred, Department of Pathology, Baylor College of Medicine, Houston, TX; D. L. DeMets, Department of Biostatistics and Medical Informatics, University of Wisconsin.
Correspondence to: Richard R. Love, M.D., M.S., 610 Walnut St., 256 WARF, Madison, WI 53705 (email: rrlove{at}facstaff.wisc.edu).
Background: It is unclear whether the phase of the menstrual cycle in which primary surgical treatment occurs influences disease-free survival (DFS) and overall survival (OS) in premenopausal women with breast cancer. We investigated this question in the context of a clinical trial comparing mastectomy alone with mastectomy plus adjuvant oophorectomy and tamoxifen in premenopausal women with operable breast cancer. Methods: The date of the first day of the last menstrual period (LMP) was used to estimate the phase of the menstrual cycle when the surgeries were done. Follicular phase was defined as day 1–14 from LMP. Luteal phase was defined as day 15–42 from LMP. DFS and OS statistics were determined and analyzed by Cox proportional hazards ratios and Kaplan–Meier methods. All statistical tests were two-sided. Results: We analyzed results for 565 women who reported an LMP within 42 days before surgery. For women in the mastectomy only arm (n = 289), there were no differences in DFS or OS by menstrual cycle phase. For women in the adjuvant treatment arm (n = 276), those whose surgery occurred during the luteal phase (n = 158) had better DFS (relative risk [RR] = 0.54; 95% confidence interval [CI] = 0.32 to 0.96; P = .02) and OS (RR = 0.53; 95% CI = 0.30 to 0.95; P = .03) than those whose surgery occurred during the follicular phase (n = 118). Moreover, women whose surgery occurred during the luteal phase and who received adjuvant therapy had better 5-year DFS than did women whose surgery occurred during the follicular phase (84%; 95% CI = 78% to 90% versus 67%; 95% CI = 58% to 78%; P = .02); they also had better OS (85%; 95% CI = 78% to 92% versus 75%; 95% CI = 66% to 84%; P = .03). Conclusions: The phase of the menstrual cycle at which surgery was done had no impact on survival for women who received mastectomy only. However, women who received a mastectomy and surgical oophorectomy and tamoxifen during the luteal phase had better outcomes than women who received surgery during the follicular phase.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. K. Nayak, H. J. Hathaway, C. Ramesh, J. B. Arterburn, D. Dai, L. A. Sklar, J. P. Norenberg, and E. R. Prossnitz Preclinical Development of a Neutral, Estrogen Receptor-Targeted, Tridentate 99mTc(I)-Estradiol-Pyridin-2-yl Hydrazine Derivative for Imaging of Breast and Endometrial Cancers J. Nucl. Med., June 1, 2008; 49(6): 978 - 986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. C. Ellis Neoadjuvant Therapy for Breast Cancer ASCO Educational Book, January 1, 2008; 2008(1): 55 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ferretti, A. Felici, P. Carlini, and F. Cognetti Re: Ovarian Ablation or Suppression in Premenopausal Early Breast Cancer: Results from the International Adjuvant Breast Cancer Ovarian Ablation or Suppression Randomized Trial J Natl Cancer Inst, September 5, 2007; 99(17): 1344 - 1345. [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Wood, K. Bove, S. You, A. Chambers, and W. J.M. Hrushesky Cancer growth and spread are saltatory and phase-locked to the reproductive cycle through mediators of angiogenesis Mol. Cancer Ther., July 1, 2005; 4(7): 1065 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Di Cosimo, A. Alimonti, G. Ferretti, I. Sperduti, P. Carlini, P. Papaldo, A. Fabi, A. Gelibter, M. Ciccarese, D. Giannarelli, et al. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer Ann. Onc., July 1, 2004; 15(7): 1065 - 1071. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ferretti, S. Di Cosimo, D. Giannarelli, P. Carlini, P. Papaldo, A. Alimonti, A. Fabi, M. Mandala, M. Milella, E. M. Ruggeri, et al. HER2/neu Expression and Hormonal Therapy in Early Breast Cancer: Can Muddy Waters Become Clear? J. Clin. Oncol., February 1, 2004; 22(3): 568 - 569. [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Vantyghem, C. O. Postenka, and A. F. Chambers Estrous Cycle Influences Organ-specific Metastasis of B16F10 Melanoma Cells Cancer Res., August 15, 2003; 63(16): 4763 - 4765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Coradini, S. Veneroni, C. Pellizzaro, and M. G. Daidone Fluctuation of intratumor biological variables as a function of menstrual timing of surgery for breast cancer in premenopausal patients Ann. Onc., June 1, 2003; 14(6): 962 - 964. [Full Text] [PDF]
|
|
|
|
|
|
M. Milella, D. Giannarelli, V. Ferraresi, M. Mottolese, C. Botti, and C. Nistico Re: Mastectomy and Oophorectomy by Menstrual Cycle Phase in Women With Operable Breast Cancer J Natl Cancer Inst, November 20, 2002; 94(22): 1719 - 1720. [Full Text] [PDF]
|
|
|
|
|
|
G. Ferretti, S. Di Cosimo, P. Carlini, P. Papaldo, A. Fabi, and F. Cognetti Re: Mastectomy and Oophorectomy by Menstrual Cycle Phase in Women With Operable Breast Cancer J Natl Cancer Inst, November 20, 2002; 94(22): 1720 - 1720. [Full Text] [PDF]
|
|
|
|
|
|
R. R. Love RESPONSE Re: Mastectomy and Oophorectomy by Menstrual Cycle Phase in Women With Operable Breast Cancer J Natl Cancer Inst, November 20, 2002; 94(22): 1721 - 1722. [Full Text] [PDF]
|
|
|
|
|
|
R. R. Love, D. C. Allred, and D. L. DeMets Re: The Influence of Menstrual Cycle Phase on Surgical Treatment of Primary Breast Cancer: Have We Made Any Progress Over the Past 13 Years? J Natl Cancer Inst, November 20, 2002; 94(22): 1722 - 1723. [Full Text] [PDF]
|
|
|
|
|
|
G. Hortobagyi RESPONSE Re: The Influence of Menstrual Cycle Phase on Surgical Treatment of Primary Breast Cancer: Have We Made Any Progress Over the Past 13 Years? J Natl Cancer Inst, November 20, 2002; 94(22): 1723 - 1723. [Full Text] [PDF]
|
|
|
|
|
|
W. J.M. Hrushesky Re: Mastectomy and Oophorectomy by Menstrual Cycle Phase in Women With Operable Breast Cancer J Natl Cancer Inst, November 20, 2002; 94(22): 1720 - 1721. [Full Text] [PDF]
|
|
|
|
|
|
R. R. Love and J. Philips Oophorectomy for Breast Cancer: History Revisited J Natl Cancer Inst, October 2, 2002; 94(19): 1433 - 1434. [Full Text] [PDF]
|
|
|
|
|
|
A. Hamilton and R. R. Love Ethical Issues Surrounding the Conduct of Off-Shore Clinical Research J. Clin. Oncol., September 15, 2002; 20(18): 3934 - 3936. [Full Text] [PDF]
|
|
|
|
 |
|
 Does Timing of Mastectomy or Oophorectomy Make a Difference? Journal Watch Women's Health, July 10, 2002; 2002(710): 4 - 4. [Full Text]
|
|
|
|
|
|
G. N. Hortobagyi The Influence of Menstrual Cycle Phase on Surgical Treatment of Primary Breast Cancer: Have We Made Any Progress Over the Past 13 Years? J Natl Cancer Inst, May 1, 2002; 94(9): 641 - 643. [Full Text] [PDF]
|
|